Revised SPC: Bavencio (avelumab) 20 mg/mL concentrate for solution for infusion

Source:
electronic Medicines Compendium - eMC
Publisher:
electronic Medicines compendium
Publication date:
01 November 2019

Abstract

SPC has been updated with additional information regarding the new licensed indication - in combination with axitinib, avelumab is licensed for the first-line treatment of adult patients with advanced renal cell carcinoma